Ugur T. Sener, MD

Ugur T. Sener, MD, discusses how findings from the INDIGO trial are influencing treatment timing after surgical resection, including evolving considerations surrounding early intervention, surveillance, fertility, and long-term management.

Ugur T. Sener, MD, discusses exploratory seizure analyses from the INDIGO trial, highlighting reductions in seizure frequency with vorasidenib and the potential biologic relationship between tumor control and epileptogenesis.

The discussion turns to the pivotal INDIGO trial, with a focus on how vorasidenib improved progression-free survival and introduced a new early treatment strategy for patients with grade 2 IDH-mutant glioma following surgery

The discussion shifts toward the biologic rationale behind vorasidenib, exploring how mutant IDH inhibition may simultaneously target tumor growth and seizure activity in patients with IDH-mutant glioma.

The discussion opens with a broad overview of seizure burden in grade 2 IDH-mutant glioma, highlighting how epilepsy affects quality of life, long-term disease management, and day-to-day functioning throughout the disease course.